충남대학교외국학술지지원센터

글로벌메뉴

  • HOME
  • sitemap

주메뉴

CNU Search

전체 ㅣ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ㅣ 가 나 다 라 마 바 사 아 자 차 카 타 파 하 기타
검색 타입
상세검색
검색어[가나다ABC : 전체]
총 7건 중 7건 출력
1/1 페이지 엑셀파일 출력
제한항목
Goodman, M 삭제
2013 삭제
검색결과제한

검색간략리스트

열거형 테이블형
검색리스트 테이블
No 자료
유형		 서명 저자 발행처 원문제공시작년 수록
매체
1 저널기사 Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada 미리보기
Goodman, M. Channing, Weinberg & Co 2013
2 저널기사 Can Isis Remain A Platform Company? 미리보기
Goodman, M. Channing, Weinberg & Co 2013
3 저널기사 Can MDCO Make Alnylam's PCSK9 Candidate Work In The Hospital? Lagging the antibodies, The Medicine's Co.'s novel approach to the PCSK9 race brings certain strenghts, not the least being a fundamentally different mechanism. Moreover, being last may not be least in a field that's changing as rapidly as lipidology 미리보기
Goodman, M. Channing, Weinberg & Co 2013
4 저널기사 Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?: Over the next three years, long-acting factor products may have a transformative effect on the hemophilia market, but will the improvements be enough to sway providers and payors? 미리보기
Goodman, M. Channing, Weinberg & Co. 2013
5 저널기사 People Power: How The Crowd May Shape The Funding And Development Of Drugs 미리보기
Goodman, M. Channing, Weinberg & Co. 2013
6 저널기사 Personalized Medicine Takes Aim At Common Diseases 미리보기
Goodman, M. Channing, Weinberg & Co 2013
7 저널기사 When Opportunity Knocks: Eisai Turns To Business Development: Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer, with an emphasis on externally sourced innovation. This put aggressive BD front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise 미리보기
Goodman, M. Channing, Weinberg & Co. 2013
1 
임시보관함보기

하단메뉴